Ken Griffin Fulcrum Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 15, 2024	SELL	$6.7 - $12.0 $27,470 - $49,200	-4,100 Reduced 53.25%	3,600 $33,000
Q4 2023 Feb 14, 2024	SELL	$3.18 - $6.86 $24,804 - $53,508	-7,800 Reduced 50.32%	7,700 $51,000
Q3 2023 Nov 14, 2023	BUY	$3.25 - $6.08 $3,900 - $7,296	1,200 Added 8.39%	15,500 $68,000
Q2 2023 Aug 14, 2023	SELL	$2.26 - $3.8 $35,030 - $58,900	-15,500 Reduced 52.01%	14,300 $47,000
Q1 2023 May 15, 2023	BUY	$2.83 - $13.99 $19,244 - $95,132	6,800 Added 29.57%	29,800 $84,000

Q4 2022 Feb 14, 2023	BUY	$5.35 - $7.28 $29,424 - $40,040	5,500 Added 31.43%	23,000 $167,000
Q3 2022 Nov 14, 2022	SELL	$4.92 - $9.1 $37,884 - $70,070	-7,700 Reduced 30.56%	17,500 $142,000

136

43.7M

3.12M

128K

Ticker FULC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,038,900
Market Cap $323M
Description
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.